Richard Kivel

Richard Kivel is a serial entrepreneur and seasoned life science & technology executive with a proven record of building successful companies, world-class teams and securing profitable exits for investors. Since April 2006 he has served as CEO of TheraGenetics, Ltd, a UK-based genetic diagnostics company focusing on the development and commercialization of pharmacogenetic diagnostic tests to guide and improve the treatment of Central Nervous System (CNS) disorders such as depression, Alzheimer’s, schizophrenia, Bipolar and ADHD. In January 2009, TheraGenetics was acquired by UK based Avacta Group plc. LSE: (AVCT). Rich has remained as CEO and continues to lead the growth of TheraGenetics under the new ownership. Prior to this, Rich has worked with and built multiple startups. From 2001-2004, he served as CEO of MolecularWare, Inc., a MIT spin-out and leader in genomic and proteomic microarray technologies. Under his leadership, MolecularWare secured venture capital and debt funding and launched multiple products. In June, 2003, the company was acquired by a California based company, CalbaTech, Inc. Since 1997, Rich has worked with multiple MIT entrepreneurial support organizations and student-driven initiatives. Rich serves as Chairman of the Global Board of Directors of the MIT Enterprise Forum and a member of the MIT Alumni Association Board. He is a frequent guest lecturer at the Institute and serves as a judge for the MIT $100K Entrepreneurship Competition. As a Lead Catalyst and Mentor for the MIT Deshpande Center for Technological Innovation, Rich works with many of the leading scientist and researchers at MIT, on early stage technology development and commercialization. Rich serves as an Advisor and Board member to startups as well as government and entrepreneurial organizations. He is a mentor for the UK Trade and Investment Global Entrepreneurs Mentoring Program and is a founding board member of Biolink USA-Ireland, a government funded membership organization. Rich is a sought after speaker and lecturer and has shared his insights on future trends in life sciences and technology and his knowledge and experience in entrepreneurship, IP, corporate finance and organizational development, with audiences throughout the US, Europe, the UK, Japan and South Africa. Rich was selected by Mass High Tech: Journal of New England Technology for the “All Star” award for leadership in Biotechnology and by the Boston Business Journal as one of its “40-under-40”; top forty most promising business people under 40 in Massachusetts.